Abdelmegeed SM, Mohammed S (2018) Canine mammary tumors as a model for human disease. Oncol Lett 15: 8195-8205.
Andaluz A, Yeste M, Rodriguez-Gil JE, Rigau T, Garcia F, Rivera del Alamo MM ( 2016) Pro-inflammatory cytokines: Useful markers for the diagnosis of canine mammary tumours? Vet J 210: 92-94.
Baba OK, Sood NK, Gupta K (2019) Clinical evaluation of glycoproteins and inflammatory cytokines in the serum of dogs affected with canine mammary cancer. Proc Natl Acad Sci India Sect B Biol Sci 89: 1465-1469.
Baker KJ, Houston A, Brint E (2019) IL-1 family members in cancer; two sides to every story. Front Immunol 10: 1197.
Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY (2004) Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10: 7157-7162.
Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9: R15.
Chen Y, Shi M, Yu GZ, Qin XR, Jin G, Chen P, Zhu MH (2012) Interleukin-8, a promising predictor for prog nosis of pancreatic cancer. World J Gastroenterol 18: 1123-1129.
Chiu JW, Hanafi ZB, Chew LC, Mei Y, Liu H (2021) IL-1α processing, signaling and its role in cancer progression. Cells 10: 92.
De Andres PJ, Illera JC, Caceres S, Diez L, Perez -Alenza MD, Pena L (2013) Increased levels of inter leukins 8 and 10 as findings of canine inflammatory mammary cancer. Vet Immunol Immunopathol 152: 245-251.
Derin D, Soydinc HO, Guney N, Tas F, Camlica H, Duranyildiz D, Yasasever V, Topuz E (2007) Serum IL-8 and IL-12 levels in breast cancer. Med Oncol 24: 163-168.
Elston CW, Ellis IO (1998) Assessment of histological grade. In: Systemic Pathology. Churchill Livingstone, London, pp 356-384.
Estrela-Lima A, Araujo MS, Soares RP, Ribeiro LG, Damasceno KA, Costa AT, Teixeira-Carvalho A, Martins-Filho OA, Cassali GD (2016) Plasma biomarkers profile of female dogs with mammary carcinoma and its association with clinical and pathological features. Vet Comp On-col 14: 88-100.
Fasoulakis Z, Kolios G, Papamanolis V, Kontomanolis EN (2018) Interleukins associated with breast cancer. Cureus 10: e3549.
Fernandes JV, Cobucci RN, Jatoba CA, Fernandes TA, de Azevedo JW, de Araujo JM (2015) The role of the mediators of inflammation in cancer development. Pathol Oncol Res 21: 527-534.
Gelaleti GB, Jardim BV, Leonel C, Moschetta MG, Zuccari DA (2012) Interleukin-8 as a prognostic serum marker in canine mammary gland neoplasias. Vet Immunol Immunopathol 146: 106-112.
Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120: 485-497.
Goldschmidt M, Pena L, Rasotto R, Zappulli V (2011) Classification and grading of canine mammary tumors. Vet Pathol 48: 117-131.
Haas M, Kaup FJ, Neumann S (2015) Evaluation of serum interleukin-8 (CXCL8) concentrations in tumor bearing dogs. Am J Anim Vet Sci 10: 202-211.
Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE, Ottewell P (2016) IL-1 drives breast cancer growth and bone metas-tasis in vivo. Oncotarget 7: 75571-75584.
Irac SE, Oksa A, Jackson K, Herndon A, Allavena R, Palmieri C (2019) Cytokine expression in canine lym phoma, osteosarcoma, mammary gland tumour and melanoma: comparative aspects. Vet Sci 6: 37.
Kim JH, Yu CH, Yhee JY, Im KS, Sur JH (2010) Lymphocyte infiltration, expression of interleukin (IL)-1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours. J Comp Pathol 142: 177-186.
Kuan EL, Ziegler SF (2018) A tumor-myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast can-cer. Nat Immunol 19: 366-374.
Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, Bigsby RM, Nakshatri H (2003) Interleukin-1α promotes tumour growth and ca-chexia in MCF-7 xenograft model of breast cancer. Am J Pathol 163: 2531-2541.
Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK (2005) Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8: 63-71.
Li L, Chen L, Zhang W, Liao Y, Chen J, Shi Y, Luo S (2017) Serum cytokine profile in patients with breast cancer. Cytokine 89: 173-178.
Lyon DE, McCain NL, Walter J, Schubert C (2008) Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 57: 51-58.
Machado VS, Crivellenti LZ, Bottari NB, Tonin AA, Pelinson LP, Borin-Crivellenti S, Santana AE, Torbitz VD, Moresco RN, Duarte T, Duarte MM, Schetinger MR, Morsch VM, Jaques JA, Tinucci-Costa M, Da Silva AS (2015) Oxidative stress and inflammatory response biomarkers in dogs with mammary carcinoma. Pathol Res Pract 211: 677-681.
Malik A, Kanneganti TD (2018) Function and regulation of IL-1α in inflammatory diseases and cancer. Immunol Rev 281: 124-137.
Maund SL, Barclay WW, Hover LD, Axanova LS, Sui G, Hipp JD, Fleet JC, Thorburn A, Cramer SD (2011) Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res 71: 5276-5286.
Maund SL, Shi L, Cramer SD (2013) A role for interleukin-1 alpha in the 1,25 dihydroxyvitamin D3 response in mammary epithelial cells. PLoS One 8: e81367.
Mohamed MM (2012) Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: A mechanism mediated by IL-8 signaling pathway. Cell Commun Signal 10: 3.
Monkong N, Thitiyanaporn C, Niyatiwatchanchai N, Jaroensong T (2020) Investigation of serum interleukin-8 level and clinicopathological parameters in canine mammary gland tumors. Vet Integr Sci 18: 173-182.
Pena L, De Andres PJ, Clemente M, Cuesta P, Perez-Alenza MD (2013) Prognostic value of histological grading in noninflammatory canine mammary carcinomas in a prospective study with two-year follow-up: relationship with clinical and histological characteristics. Vet Pathol 50: 94-105.
Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in tumor growth. Cancer Lett 256: 137-165.
Salas Y, Marquez A, Diaz D, Romero L (2015) Epidemiolo gical study of mammary tumors in female dogs diagnosed during the period 2002-2012. A growing animal health problem. PLoS One 10: e0127381.
Salvatore V, Teti G, Focaroli S, Mazzotti MC, Mazzotti A, Falconi M (2017) The tumor microenvironment promotes cancer progression and cell migration. Oncotarget 8: 9608-9616.
Salven P, Hattori K, Heissig B, Rafii S (2002) Interleukin-1 alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflam-matory cell VEGF synthesis and secretion. FASEB J 16: 1471-1473.
Simeone AM, Nieves-Alicea R, McMurtry VC, Colella S, Krahe R, Tari AM (2007) Cyclooxygenase-2 uses the protein kinase C/interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int J Oncol 30: 785-792.
Singer CF, Hudelist G, Gschwantler-Kaulich D, Fink -Retter A, Mueller R, Walter I, Czerwenka K, Kubista E (2006) Interleukin-1 alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity. Int J Gynecol Cancer 16 (Suppl 2): 556-559.
Sleeckx N, de Rooster H, Veldhuis Kroeze EJ, Van Ginneken C, Van Brantegem L (2011) Canine mammary tumours, an overview. Reprod Domest Anim 46: 1112-1131.
Tjomsland V, Spangeus A, Vӓlilӓ J, Sandstrӧm P, Borch K, Druid H, Falkmer S, Falkmer U, Messmer D, Larsson M (2011) Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neo-plasia 13: 664-675.
Todorović-Raković N, Milovanović J (2013) Interleukin-8 in breast cancer progression. J Interferon Cytokine Res 33: 563-570.
Yokoe T, Iino Y, Takei H, Horiguchi J, Koibuchi Y, Maemura M, Ohwada S, Morishita Y (1997) Changes of cytokines and thyroid function in patients with recurrent breast cancer. Anticancer Res 17: 695-699.
Yuan A, Chen JJ, Yao PL, Yang PC (2005) The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 10: 853-865.

1. Abdelmegeed SM, Mohammed S (2018) Canine mammary tumors as a model for human disease. Oncol Lett 15: 8195-8205.
2. Aljurany AN, Samarrai OR (2022) Evaluation of chemokine CXCL12 level with oxidative stress in breast cancer. Int J Health Sci 6: 6382-6392.
3. Allende C, Higgins B, Johns J (2020) Comparison of serum cytokine concentrations between healthy dogs and canine osteosarcoma patients at the time of diagnosis. Vet Immunol Immunopathol 227: 110084.
4. Ariyarathna H, Thomson N, Aberdein D, Munday JS (2020) Chemokine gene expression influences metastasis and survival time of female dogs with mammary carcinoma. Vet Immunol Immunopathol 227: 110075.
5. Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE (2007) Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep 17: 687-694.
6. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29: 313-326.
7. Elston CW, Ellis IO (1998) Assessment of histological grade. In: Systemic Pathology. Churchill Livingstone, London, pp 356-384.
8. Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng Z, Liu L (2020) Serum level of CCL2 predicts outcome of patients with pancreatic cancer. Acta Gastroenterol Belg 83: 295-299.
9. Ferrari SM, Elia G, Piaggi S, Baldini E, Ulisse S, Miccoli M, Materazzi G, Antonelli A, Fallahi P (2018) CCL2 is modulated by cytokines and PPAR-γ in anaplastic thyroid cancer. Anticancer Agents Med Chem 18: 458-466.
10. Gao D, Fish EN (2018) Chemokines in breast cancer: Regulating metabolism. Cytokine 109: 57-64.
11. Goldschmidt M, Pena L, Rasotto R, Zappulli V (2011) Classification and grading of canine mammary tumors. Vet Pathol 48: 117-131.
12. Hayasaka H, Yoshida J, Kuroda Y, Nishiguchi A, Matsusaki M, Kishimoto K, Nishimura H, Okada M, Shimomura Y, Kobayashi D, Shimazu Y, Taya Y, Akashi M, Miyasaka M (2022) CXCL12 promotes CCR7 ligand-mediated breast cancer cell invasion and migration toward lymphatic vessels. Cancer Sci 113: 1338-1351.
13. Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, Leodolter S, Reinthaller A, Kainz C (1999) Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 81: 855-859.
14. Im KS, Graef AJ, Breen M, Lindblad-Toh K, Modiano JF, Kim JH (2017) Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma. Vet Comp Oncol 15: 315-327.
15. Ishioka K, Suzuki Y, Tajima K, Ohtaki S, Miyabe M, Takasaki M, Mori A, Momota Y, Azakami D, Sako T (2013) Monocyte chemoattractant protein-1 in dogs affected with neoplasia or inflammation. J Vet Med Sci 75: 173-177.
16. Janssens R, Struyf S, Proost P (2018) The unique structural and functional features of CXCL12. Cell Mol Immunol 15: 299-311.
17. Kohli K, Pillarisetty VG, Kim TS (2022) Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther 29: 10-21.
18. Li H, Wu M, Zhao X (2022) Role of chemokine systems in cancer and inflammatory diseases. MedComm 3: e147.
19. Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ (2016) Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 7: 28697-28710.
20. Lu X, Kang Y (2009) Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284: 29087-29096.
21. Lu X, Qian CN, Mu YG, Li NW, Li S, Zhang HB, Li SW, Wang FL, Guo X, Xiang YQ (2011) Serum CCL2 and serum TNF-α – Two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma. Eur J Cancer 47: 339-346.
22. Lubowicka E, Przylipiak A, Zajkowska M, Piskór BM, Malinowski P, Fiedorowicz W, Ławicki S (2018) Plasma chemokine CCL2 and its receptor CCR2 concentrations as diagnostic biomarkers for breast cancer patients. Biomed Res Int 2018: 2124390.
23. Maekawa N, Konnai S, Asano Y, Sajiki Y, Deguchi T, Okagawa T, Watari K, Takeuchi H, Takagi S, Hosoya K, Kim S, Ohta H, Kato Y, Suzuki Y, Murata S, Ohashi K (2022) Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. Sci Rep 12: 9265.
24. Marques CS, Santos AR, Gameiro A, Correia J, Ferreira F (2018) CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors. BMC Cancer 18: 741.
25. Marques CS, Soares M, Santos A, Correia J, Ferreira F (2017) Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes. Oncotarget 8: 105775-105789.
26. Nielsen LN, Kjelgaard-Hansen M, Kristensen AT (2013) Monocyte chemotactic protein-1 and other inflammatory parameters in Bernese Mountain dogs with disseminated histiocytic sarcoma. Vet J 198: 424-428.
27. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
28. Pan YW, Zhou ZG, Wang M, Dong JQ, Du KP, Li S, Liu YL, Lv PJ, Gao JB (2016) Combination of IL6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis. Genet Mol Res 15: gmr15048949.
29. Pena L, De Andres PJ, Clemente M, Cuesta P, Perez-Alenza MD (2013) Prognostic value of histological grading in noninflammatory canine mammary carcinomas in a prospective study with two-year follow-up: relationship with clinical and histological characteristics. Vet Pathol 50: 94-105.
30. Perry JA, Thamm DH, Eickhoff J, Avery AC, Dow SW (2011) Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma. Vet Comp Oncol 9: 55-64.
31. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225.
32. Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in tumor growth. Cancer Lett 256: 137-165.
33. Rybicka A, Eyileten C, Taciak B, Mucha J, Majchrzak K, Hellmen E, Krol M (2016) Tumour-associated macrophages influence canine mammary cancer stem-like cells enhancing their pro-angiogenic properties. J Physiol Pharmacol 67: 491-500.
34. Salas Y, Marquez A, Diaz D, Romero L (2015) Epidemiological study of mammary tumors in female dogs diagnosed during the period 2002-2012: a growing animal health problem. PLoS One 10: e0127381.
35. Sanchez-Martin L, Estecha A, Samaniego R, Sanchez-Ramon S, Vega MA, Sanchez-Mateos P (2011) The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117: 88-97.
36. Shi Y, Riese DJ 2nd, Shen J (2020) The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front Pharmacol 11: 574667.
37. Shimizu N, Hamaide A, Dourcy M, Noёl S, Clercx C, Teske E (2019) Evaluation of urinary and serum level of chemokine (C-C motif) ligand 2 as a potential biomarker in canine urothelial tumours. Vet Comp Oncol 17: 11-20.
38. Sleeckx N, de Rooster H, Veldhuis Kroeze EJ, Van Ginneken C, Van Brantegem L (2011) Canine mammary tumours, an overview. Reprod Domest Anim 46: 1112-1131.
39. Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267: 271-285.
40. Tang CH, Tsai CC (2012) CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway. Biochem Pharmacol 83: 335-344.
41. Wu J, Liu X, Wang Y (2013) Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer. BMC Clin Pathol 13: 15.
42. Yao M, Yu E, Staggs V, Fan F, Cheng N (2016) Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers. Mod Pathol 29: 810-823.
43. Zielińska KA, Katanaev VL (2020) The signaling duo CXCL12 and CXCR4: chemokine fuel for breast cancer tumorigenesis. Cancers (Basel) 12: 3071.